Franklin Genomic Advancements ETF
HELX
6 hedge funds and large institutions have $3.78M invested in Franklin Genomic Advancements ETF in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
124% more capital invested
Capital invested by funds: $1.69M → $3.78M (+$2.09M)
6.7% more ownership
Funds ownership: 7.85% → 14.55% (+6.7%)
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.33M |
| 2 |
LPL Financial
San Diego,
California
|
+$302K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$27.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$131K |
| 2 |
HI
Harbour Investments
Madison,
Wisconsin
|
-$13.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.94K |
HELX Hedge Fund Activity: Q2 2026 in Review
6 of the 8,337 institutional investors tracked by Wall St. Rank reported a position in Franklin Genomic Advancements ETF (HELX) for Q2 2026, worth a combined $3.78M — up 124% from $1.69M a quarter earlier.
Fund positioning in HELX was balanced in Q2 2026: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 2 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $1.33M. The largest seller was Citadel Advisors, cutting an estimated $131K.
- 6 institutional investors held Franklin Genomic Advancements ETF (HELX) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $3.78M of Franklin Genomic Advancements ETF stock for Q2 2026, up 124% quarter-over-quarter.
- 1 fund opened new Franklin Genomic Advancements ETF positions in Q2 2026 and 1 closed out, a net change of 0 holders.
- The largest Franklin Genomic Advancements ETF buyer in Q2 2026 was Susquehanna International Group, an estimated $1.33M added.
- The largest Franklin Genomic Advancements ETF seller in Q2 2026 was Citadel Advisors, an estimated $131K sold.
Based on aggregated 13F filings for Q2 2026.